December 28, 2014 5:28 PM ET

Healthcare Equipment and Supplies

Company Overview of Roka Bioscience, Inc.

Company Overview

Roka Bioscience, Inc., a molecular diagnostics company, focuses on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens in the United States. It provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin-producing E. coli, and Listeria monocytogenes, as well as related consumable supplies. It serves contract testing labs, food processors, and government agencies. The company was founded in 2009 ...

20 Independence Boulevard

4th Floor

Warren, NJ 07059

United States

Founded in 2009

130 Employees

Phone:

908-605-4700

Key Executives for Roka Bioscience, Inc.

Founder
Age: 58
Total Annual Compensation: $457.7K
Chief Financial Officer
Age: 57
Total Annual Compensation: $296.2K
Senior Vice President and General Manager
Age: 60
Total Annual Compensation: $296.2K
Compensation as of Fiscal Year 2013.

Roka Bioscience, Inc. Key Developments

Roka Bioscience, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 04:30 PM

Roka Bioscience, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 04:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Paul G. Thomas, Founder, Chief Executive Officer, President and Director.

Roka Bioscience, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Roka Bioscience, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of $1,483,000 against $556,000 a year ago. Loss from operations was $8,373,000 against $7,268,000 a year ago. Loss before income taxes was $9,072,000 against $9,414,000 a year ago. Net loss and comprehensive loss was $9,083,000 against $9,449,000 a year ago. Basic and diluted net loss per share was $0.64 against $17.00 a year ago. The increase in third quarter revenue year-on-year resulted from an increase in the number of Atlas(R) instruments placed with commercial customers and increased commercial utilization of the instruments. For the nine months, the company reported revenue of $3,701,000 against $1,493,000 a year ago. Loss from operations was $22,742,000 against $22,194,000 a year ago. Loss before income taxes was $24,771,000 against $25,069,000 a year ago. Net loss and comprehensive loss was $24,799,000 against $25,105,000 a year ago. Basic and diluted net loss per share was $4.78 against $51.05 a year ago.

Roka Bioscience, Inc. to Report Q3, 2014 Results on Nov 06, 2014

Roka Bioscience, Inc. announced that they will report Q3, 2014 results After-Market on Nov 06, 2014

Similar Private Companies By Industry

Company Name Region
Hospital Systems, Inc. United States
Physiologic Communications, LLC United States
Separation Technology Inc. United States
Prodigy Diabetes Care, LLC United States
Aesthetic Concerns Prosthetics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Roka Bioscience, Inc., please visit www.rokabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.